Document:

Document

Exhibit 10.2
SECOND AMENDMENT OF LEASE

This Second Amendment of Lease is made on October 11, 2021, between Liberty Vista, a California limited partnership, ("Lessor"), whose address is 1000 Pioneer Way, El Cajon, CA 92020, and Exagen Diagnostics, Inc., ("Lessee"), with reference to 1221 Liberty Way, San Diego, CA 92083 who agree as follows:

1.Recitals. This Second Amendment of Lease is made with reference to the following facts and objectives:
a.Lessor and Lessee entered into a written Lease dated August 15, 2014, as extended February 1, 2018, February 25, 2020, as amended December30, 2020 ("the Lease") in which Lessor leased to Lessee, and Lessee leased from Lessor, premises located in the City of Vista, County of San Diego, California, commonly known as 1221 Liberty Way, Vista, CA 92083, consisting of approximately 19,504 square feet (“Premises”).
b.The term of the Lease expires on January 31, 2026.
c.The parties desire to amend the Lease in the following respect:
2.Extension of Term.  The term of the Lease shall be extended for an additional period of one (1) year and three (3) months from and after February 1, 2026, so that the term of the Lease shall extend to and include April 30, 2027.
3.Base Monthly Rent Schedule.  Base monthly rent for the current and extended term shall be as follows:												
	Term	Base Rent	Additional Base Rent (Amortized TIA)
	Total Base Rent
	February 1, 2021 through January 31, 2022	$	19,000.00 		$	990.00 		$	19,990.00 	
	February 1, 2022 through January 31, 2023	$	19,600.00 		$	990.00 		$	20,590.00 	
	February 1, 2023 through January 31, 2024	$	20,200.00 		$	990.00 		$	21,190.00 	
	February 1, 2024 through January 31, 2025	$	20,800.00 		$	990.00 		$	21,790.00 	
	February 1, 2025 through January 31, 2026	$	21,400.00 		$	990.00 		$	22,390.00 	
	February 1, 2026 through January 31, 2027	$	22,470.00 		$	0.00 		$	22,470.00 	
	February 1, 2027 through April 30, 2027	$	23,594.00 		$	0.00 		$	23,594.00 	

4.Lessor Ownership Correction.  The Lessor of the premises erroneously appeared as “Liberty Vista, a California limited partnership”. The correct Lessor name is "Liberty Vista, LP, a California limited partnership". The Lessor name is hereby corrected throughout the Lease.
5.Lessee Name Change.  The Lessee's name shall change from Exagen Diagnostics, Inc., a California corporation to Exagen Inc. a California corporation.
6.Counterparts.  The Amendment may be signed by the parties in different counterparts and the signature pages combined shall create a single document binding on all parties. This Amendment may be executed and delivered by the exchange of .pdf or using electronic signature technology (e.g., via DocuSign or similar electronic signature technology), and such signed electronic record shall be valid and bind the party so signing as a such party's hand-written signature for all purposes.
7.Effectiveness of Lease.  Except as set forth in this Second Amendment of Lease, all the provisions of the Lease shall remain unchanged and in full force and effect.

									
	LESSOR:		LESSEE:
	Liberty Vista, LP		Exagen Inc.
	A California Limited Partnership		A Delaware Corporation
	By: Hamann Property Management, Inc.		
	Its Authorized Agent		
			
	By: /s/ Brendan Thiessen		By: /s/ Fortunato Ron Rocca
	Brendan Thiessen - President		Fortunato Ron Rocca, President & CEO
	Date: 10/13/2021		Date: 10/12/2021
			
			By: /s/ Mark Hazeltine
			Mark Hazeltine, COO
			Date: 10/12/2021Document

Exhibit 10.3

FIFTH ADDENDUM TO STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET DATED JANUARY 13, 2012 BY AND BETWEEN RGS PROPERTIES, AS LESSOR AND EXAGEN DIAGNOSTICS, INC., AS LESSEE, FOR THE PREMISES LOCATED AT 1261 LIBERTY WAY, SUITES B & C, CALIFORNIA.

Lessor and Lessee mutually agree to amend the lease as follows:

Parties (1.1):
Lessee has changed their name and shall here for be referred to as Exagen Inc., a Delaware Corporation

Paragraph 1.3 (Term):
The Lease Term will be extended to the new Expiration Date of April 30, 2027

Paragraph 50 (Rent Schedule):
Base Rent shall be as follows:

						
	Dates	Base Rent
	February 1, 2026 - April 30, 2027	$20,084.42 per month

All other terms and conditions of the existing Lease shall remain in full force and effect.

This addendum shall automatically expire is not executed by Lessee on or before Friday October 15, 2021.

AGREED AND ACCEPTED:

									
	LESSOR:		LESSEE:
	RGS Properties		Exagen Inc., a Delaware Corporation
			
	By: /s/ Scott Smith		By: /s/ Ron Rocca
	By: /s/ Greg Smith		Ron Rocca
	Date: 10/19/2021		Title: CEO
			Date: 10/12/2021Document

Exhibit 10.4

FIRST ADDENDUM TO STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET DATED FEBRUARY 27, 2020 BY AND BETWEEN RGS PROPERTIES, AS LESSOR AND EXAGEN DIAGNOSTICS, INC., AS LESSEE, FOR THE PREMISES LOCATED AT 1261 LIBERTY WAY, SUITE A, CALIFORNIA.

Lessor and Lessee mutually agree to amend the lease as follows:

Parties (1.1):
Lessee has changed their name and shall be referred to as Exagen Inc., a Delaware Corporation

Paragraph 1.3 (Term):
The Lease Term will be extended to the new Expiration Date of April 30, 2027

Paragraph 50 (Rent Schedule):
Base Rent shall be as follows:

						
	Dates	Base Rent
	February 1, 2026 - April 30, 2027	$14,750.63 per month

All other terms and conditions of the existing Lease shall remain in full force and effect.

This addendum shall automatically expire if not executed by Lessee on or before Friday October 15, 2021.

AGREED AND ACCEPTED:

									
	LESSOR:		LESSEE:
	RGS Properties		Exagen Inc., a Delaware Corporation
			
	By: /s/ Scott Smith		By: /s/ Ron Rocca
	By: /s/ Greg Smith		Ron Rocca
	Date: 10/19/2021		Title: CEO
			Date: 10/12/2021Document

Exhibit 10.5

SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT

This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into effective as of November 1, 2021, by and among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership (together with its successors and assigns, “Innovatus”), as collateral agent (in such capacity, together with its successors and assigns in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 thereof or otherwise a party thereto from time to time (each a “Lender” and collectively, “Lenders”), and EXAGEN INC., a Delaware corporation (f/k/a EXAGEN DIAGNOSTICS, INC.) (“Borrower”).

RECITALS

A.    Collateral Agent, Lenders, and Borrower have entered into that certain Loan and Security Agreement dated as of September 7, 2017 (as the same may from time to time be amended, modified, supplemented or restated, the “Loan Agreement”).

B.    Lenders have extended credit to Borrower for the purposes permitted in the Loan Agreement.

C.    Borrower has requested that Collateral Agent and Lenders amend the Loan Agreement as more fully set forth herein.

D.    Collateral Agent and Lenders have agreed to amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below.

E.    As of November 1, 2021, the outstanding principal balance of the Term Loans, including payable in-kind interest which has been capitalized, is $27,203,341.00 (See Annex X).

AGREEMENT

NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:

1.    Definitions.  Capitalized terms used but not defined in this Agreement shall have the meanings given to them in the Loan Agreement.

2.    Amendments.

2.1    Section 2.3 (Payment of Interest on the Term Loan).  Section 2.3(a) of the Loan Agreement is amended and restated as follows:

(a)    Interest Rate.  Subject to Section 2.3(b), the principal amount outstanding under the Term Loan shall accrue interest at a fixed per annum rate equal to percent (8.00%) prior to , which interest shall be payable monthly in arrears in accordance with Sections 2.2(b) and 2.3(e); provided that two percent (2.00%) of such eight percent (8.00%) interest rate shall be payable in-kind through December 1, 2024 by adding an amount equal to such two percent (2.00%) interest to the then outstanding principal balance on a monthly basis so as to increase the outstanding principal balance of such Term Loan on each Payment Date and which amount shall be payable when the principal amount of the Term Loan is payable in accordance with Sections 2.2(b) and 2.3(e) and on which principal amount interest shall be owed pursuant to Section 2.3(a).

2.2    Section 6.15 (Performance to Plan).  A new Section 6.15 is added to the Loan Agreement as follows:

6.15    Performance to Plan.  So long as the Performance Period is not in effect, Borrower shall achieve minimum trailing twelve (12) month revenue under GAAP, measured at the end of each calendar quarter commencing with the quarter ending December 31, 2022, greater than sixty-five percent (65%) of projected revenue under GAAP (such projections attached hereto as Annex Q, the “Management Plan”) (the “Performance Covenant”). Borrower’s failure to maintain the Performance Covenant may be cured by the Equity Cure. Upon the Equity Cure, the Performance Covenant shall be based on the New Management Plan.

2.7    Section 13 (Definitions).  The following terms and their definition are added to or amended and restated in Section 13 of the Loan Agreement as follows:

“Amortization Date” is January 1, 2025.

“Maturity Date” is November 19, 2026.

“Second Amendment Effective Date” is November 1, 2021.

“Prepayment Fee” is, with respect to any Term Loan subject to prepayment prior to the Maturity Date, whether by mandatory or voluntary prepayment, acceleration or otherwise, as indicated, an additional fee payable to the Lenders in amount equal to:

(i)    for any prepayment made after the Second Amendment Effective Date through and including the first anniversary of the Second Amendment Effective Date, which, pursuant to Section 2.2(d), may not be a voluntary prepayment, three percent (3.00%) of the principal amount of the Term Loan prepaid;

(ii)    for any prepayment made after the first anniversary of the Second Amendment Effective Date through and including the second anniversary of the Second Amendment Effective Date, two percent (2.00%) of the principal amount of the Term Loan prepaid;

(iii)    for any prepayment made after the second anniversary of the Second Amendment Effective Date through and including the third anniversary of the Second Amendment Effective Date, one percent (1.00%) of the principal amount of the Term Loan prepaid; and

(iv)    for any prepayment made after the third anniversary of the Second Amendment Effective Date, zero percent (0%) of the principal amount of the Term Loan prepaid.

2.8    Annex Q (Management Plan) to the Loan Agreement is replaced with Annex Q attached hereto.

2.9    Annex X (Loan Interest Rate and Payment of Principal Schedule) to the Loan Agreement is replaced with Annex X attached hereto.

3.    Limitation of Agreement.

3.1    This Agreement is effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Collateral Agent and Lenders may now have or may have in the future under or in connection with any Loan Document.

3.2    This Agreement shall be construed in connection with and as part of the Loan Documents, and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents are hereby ratified and confirmed and shall remain in full force and effect.

4.    Representations and Warranties.  Borrower represents and warrants to Collateral Agent and Lenders as follows:

4.1    (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing immediately before and after giving effect to this Agreement;

4.2    Borrower has the power and authority to execute and deliver this Agreement and to perform its obligations under the Loan Agreement;

4.3    The organizational documents of Borrower delivered to Collateral Agent and Lenders on the Effective Date or subsequent thereto remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;

4.4    The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement have been duly authorized by all necessary action on the part of Borrower;

4.5    The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement do not and will not contravene (a) any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower;

4.6    The execution and delivery by Borrower of this Agreement and the performance by Borrower of its obligations under the Loan Agreement do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on either Borrower, except as already has been obtained or made; and

4.7    This Agreement has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights.

5.    Prior Agreement.  The Loan Documents are hereby ratified and reaffirmed and shall remain in full force and effect. This Agreement is not a novation and the terms and conditions of this Agreement shall be in addition to and supplemental to all terms and conditions set forth in the Loan Documents. In the event of any conflict or inconsistency between this Agreement and the terms of such documents, the terms of this Agreement shall be controlling, but such document shall not otherwise be affected or the rights therein impaired.

6.    Integration.  This Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.

7.    Counterparts.  This Agreement may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.

8.    Conditions to Effectiveness.  This Agreement shall be deemed effective upon the due execution and delivery to Collateral Agent and Lenders, in form and substance reasonably satisfactory to Collateral Agent and each Lender, such documents, and completion of such other matters, as Collateral Agent and each Lender may reasonably deem necessary or appropriate (and requested in writing at least three Business Days prior to the date hereof), including, without limitation:

a) this Agreement duly executed by each party hereto; and

b) a duly executed corporate borrowing certificate dated as of the date hereof.

9.    Miscellaneous.

9.1    This Agreement shall constitute a Loan Document under the Loan Agreement; the failure to comply with the covenants contained herein shall constitute an Event of Default under the Loan Agreement; and all obligations included in this Agreement (including, without limitation, all obligations for the payment of principal, interest, fees, and other amounts and expenses) shall constitute obligations under the Loan Agreement and secured by the Collateral.

9.2    Each provision of this Agreement is severable from every other provision in determining the enforceability of any provision.

10.    Governing Law.  This Agreement and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of New York.

[Signature pages follow]

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above.

									
	BORROWER:	

	

	

	

	

	EXAGEN INC.	

	

	

	

	

	By: /s/Kamal Adawi
	

	

	Name: Kamal Adawi
	

	

	Title: CFO
	

	

	

	

	

	

	

	

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above.

									
	COLLATERAL AGENT AND LENDER:	

	

	

	

	

	INNOVATUS LIFE SCIENCES LENDING FUND I, LP
	

	

	

	By: Innovatus Life Sciences GP, LP
Its: General Partner

	

	

	By: /s/ Andrew Dym    
	

	

	Name: Andrew Dym
	

	

	Title: Authorized Signatory
	

	

ANNEX Q

(Management Plan)

ANNEX X

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]